Late-Stage Trials of GSK's Asthma Drug Meet Objectives
Tuesday, 21 May 2024, 07:10
GSK's Potential Blockbuster Asthma Drug Trials Succeed
GSK announced the successful results of two late-stage trials for an asthma drug with the potential for over £3 billion in peak sales. The trials met their goals, marking a significant milestone in the drug's development. The positive outcome is expected to bolster GSK's position in the pharmaceutical market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.